The role of caveolin-1 in prostate cancer: Clinical implications

T. C. Thompson, S. A. Tahir, L. Li, M. Watanabe, K. Naruishi, G. Yang, D. Kadmon, C. J. Logothetis, P. Troncoso, C. Ren, A. Goltsov, S. Park

Research output: Contribution to journalReview articlepeer-review

79 Citations (Scopus)


Caveolin-1 (cav-1) is reportedly overexpressed in prostate cancer cells and is associated with disease progression. Specific oncogenic activities of cav-1 associated with Akt activation also occur in prostate cancer. A membrane-associated protein, cav-1, is nonetheless secreted by prostate cancer cells; results of recent studies showed that secreted cav-1 can stimulate cell survival and angiogenic activities, defining a role for cav-1 in the prostate cancer microenvironment. Serum cav-1 levels were also higher in prostate cancer patients than in control men without prostate cancer, and the preoperative serum cav-1 concentration had prognostic potential in men undergoing radical prostatectomy. Secreted cav-1 is therefore a potential biomarker and therapeutic target for prostate cancer.

Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Issue number1
Publication statusPublished - Mar 2010


  • Angiogenesis
  • Biomarkers
  • Caveolin-1
  • Progression

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research


Dive into the research topics of 'The role of caveolin-1 in prostate cancer: Clinical implications'. Together they form a unique fingerprint.

Cite this